Standard

Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination. / Ivanov, Alexey; Shamagsumova, Rezeda; Larina, Marina et al.
In: Biosensors, Vol. 14, No. 2, 2024, p. 93.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Ivanov A, Shamagsumova R, Larina M, Evtugyn G. Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination. Biosensors. 2024;14(2):93. doi: 10.3390/bios14020093

Author

Ivanov, Alexey ; Shamagsumova, Rezeda ; Larina, Marina et al. / Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination. In: Biosensors. 2024 ; Vol. 14, No. 2. pp. 93.

BibTeX

@article{82ea8632b467456a9184b06950cd0bc9,
title = "Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer{\textquoteright}s Disease Drug Determination",
abstract = "Neurodegenerative diseases and Alzheimer{\textquoteright}s disease (AD), as one of the most common causes of dementia, result in progressive losses of cholinergic neurons and a reduction in the presynaptic markers of the cholinergic system. These consequences can be compensated by the inhibition of acetylcholinesterase (AChE) followed by a decrease in the rate of acetylcholine hydrolysis. For this reason, anticholinesterase drugs with reversible inhibition effects are applied for the administration of neurodegenerative diseases. Their overdosage, variation in efficiency and recommendation of an individual daily dose require simple and reliable measurement devices capable of the assessment of the drug concentration in biological fluids and medications. In this review, the performance of electrochemical biosensors utilizing immobilized cholinesterases is considered to show their advantages and drawbacks in the determination of anticholinesterase drugs. In addition, common drugs applied in treating neurodegenerative diseases are briefly characterized. The immobilization of enzymes, nature of the signal recorded and its dependence on the transducer modification are considered and the analytical characteristics of appropriate biosensors are summarized for donepezil, huperzine A, rivastigmine, eserine and galantamine as common anti-dementia drugs. Finally, the prospects for the application of AChE-based biosensors in clinical practice are discussed.",
author = "Alexey Ivanov and Rezeda Shamagsumova and Marina Larina and Gennady Evtugyn",
note = "This work was funded by the subsidy allocated to the Kazan Federal University for the state assignment in the sphere of scientific activities (grant No FZSM-2023-0018).",
year = "2024",
doi = "10.3390/bios14020093",
language = "English",
volume = "14",
pages = "93",
journal = "Biosensors",
issn = "2079-6374",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

RIS

TY - JOUR

T1 - Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer’s Disease Drug Determination

AU - Ivanov, Alexey

AU - Shamagsumova, Rezeda

AU - Larina, Marina

AU - Evtugyn, Gennady

N1 - This work was funded by the subsidy allocated to the Kazan Federal University for the state assignment in the sphere of scientific activities (grant No FZSM-2023-0018).

PY - 2024

Y1 - 2024

N2 - Neurodegenerative diseases and Alzheimer’s disease (AD), as one of the most common causes of dementia, result in progressive losses of cholinergic neurons and a reduction in the presynaptic markers of the cholinergic system. These consequences can be compensated by the inhibition of acetylcholinesterase (AChE) followed by a decrease in the rate of acetylcholine hydrolysis. For this reason, anticholinesterase drugs with reversible inhibition effects are applied for the administration of neurodegenerative diseases. Their overdosage, variation in efficiency and recommendation of an individual daily dose require simple and reliable measurement devices capable of the assessment of the drug concentration in biological fluids and medications. In this review, the performance of electrochemical biosensors utilizing immobilized cholinesterases is considered to show their advantages and drawbacks in the determination of anticholinesterase drugs. In addition, common drugs applied in treating neurodegenerative diseases are briefly characterized. The immobilization of enzymes, nature of the signal recorded and its dependence on the transducer modification are considered and the analytical characteristics of appropriate biosensors are summarized for donepezil, huperzine A, rivastigmine, eserine and galantamine as common anti-dementia drugs. Finally, the prospects for the application of AChE-based biosensors in clinical practice are discussed.

AB - Neurodegenerative diseases and Alzheimer’s disease (AD), as one of the most common causes of dementia, result in progressive losses of cholinergic neurons and a reduction in the presynaptic markers of the cholinergic system. These consequences can be compensated by the inhibition of acetylcholinesterase (AChE) followed by a decrease in the rate of acetylcholine hydrolysis. For this reason, anticholinesterase drugs with reversible inhibition effects are applied for the administration of neurodegenerative diseases. Their overdosage, variation in efficiency and recommendation of an individual daily dose require simple and reliable measurement devices capable of the assessment of the drug concentration in biological fluids and medications. In this review, the performance of electrochemical biosensors utilizing immobilized cholinesterases is considered to show their advantages and drawbacks in the determination of anticholinesterase drugs. In addition, common drugs applied in treating neurodegenerative diseases are briefly characterized. The immobilization of enzymes, nature of the signal recorded and its dependence on the transducer modification are considered and the analytical characteristics of appropriate biosensors are summarized for donepezil, huperzine A, rivastigmine, eserine and galantamine as common anti-dementia drugs. Finally, the prospects for the application of AChE-based biosensors in clinical practice are discussed.

UR - http://www.scopus.com/inward/record.url?partnerID=8YFLogxK&scp=85185714550

UR - https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=tsmetrics&SrcApp=tsm_test&DestApp=WOS_CPL&DestLinkType=FullRecord&KeyUT=001172087400001

U2 - 10.3390/bios14020093

DO - 10.3390/bios14020093

M3 - Review article

VL - 14

SP - 93

JO - Biosensors

JF - Biosensors

SN - 2079-6374

IS - 2

ER -

ID: 53802091